Abstract
Introduction
Actinic keratosis (AK) is an epidermal manifestation of abnormal keratinocyte proliferation caused by exposure to ultraviolet radiation. With an estimated prevalence of between 1.4 and 25% of the population [1] [2] [3] [4] [5] , it is the most common premalignant condition in the Caucasian population. AKs usually are present as scaly, red lesions which may adhere to clothing, itch, or bleed and can therefore cause an uncomfortable physical experience. They are mostly located on skin areas chronically exposed to ultraviolet radiation, such as the face, scalp and dorsal hands, thereby also causing cosmetic discomfort to the patient. Due to its premalignant nature the fear of developing skin cancer often arises, which could lead to anxiety and stress. Therefore, patients with AK may have health-related quality of life (HRQoL) impairment.
To determine the influence of dermatological diseases on this HRQoL, there are several instruments available [6, 7] . These are generic questionnaires and are used for a variety of diseases in dermatology, which makes it possible to compare the burden of different conditions. As they are not disease-specific they might miss important aspects that have a great impact on the quality of life of specific patient groups. Therefore, the AKQoL was developed in 2012.
It was the first disease-specific questionnaire for AK, which was demonstrated to be valid and to have an excellent internal consistency, a high reproducibility, and a high responsiveness. It appears to be a valuable instrument for assessing improvement in patients' HRQoL in both clinical practice and trials [8] .
Although the AKQoL has been frequently used, documenting and testing its psychometric properties has been limited to the Spanish [9, 10] and Danish populations (original study [8] ). Therefore, the objective of this study is to test the psychometric properties of the Dutch version of the AKQoL (AKQoL-NL) in a heterogeneous group of Dutch patients diagnosed with AK.
Materials and Methods
For further details, see the online supplementary material (see www.karger.com/doi/10.1159/000489118 for all online suppl. material) [7, [11] [12] [13] [14] [15] [16] [17] [18] (Fig. 1) .
Results

Study Population
Of the 198 AK patients who were screened for inclusion, 190 were eligible, of whom 153 consented to participate (81%). The other 37 declined due to lack of time or interest. The mean age of the participants was 75 years, almost 60% were men, and the most common AK local- ization was the face. Most participants (95%) were re-interviewed after 2 weeks (Table 1) .
Feasibility
There were no missing data: all of the patients responded to all items. Floor effects ≥85% were found in items 2, 3 (single-item subscale "global"), 5, 6, and 8. No floor effects were found in the other subscales or in the total scale.
Reliability
The item responses of the first assessment of the domains of the AKQoL-NL showed a poor internal consistency (Cronbach α = 0.235, 0.297, and 0.468) ( Table 2 ). The correlations between domains were lower than those obtained in the original scale of Esmann et al. [8] and in the two Spanish validation studies ( Table 3 ).
The test-retest reliability (or "repeatability"), which was analyzed twice (2 weeks apart) among the 146 patients who completed the AKQoL, was excellent for all domains (Table 4) .
Validity
Construct Validity. The AKQoL correlated poorly with both the SS and the PSS of the Skindex-17, which was used to test convergent validity ( Table 5 ). The correlation with the domains of the GFI (divergent validity) were lower.
Discriminative Validity. The mean of the AKQoL total scores increased significantly with the severity of AK. The mean scores of patients with mild AK were 2.81 (SD = 2.67), 3 1 Esmann et al. [8] . 2 Longo Imedio et al. [9] . 3 Alarcon et al. [10] . severe AK (Table 6 ; p < 0.001) with a significant difference between the moderate AK and severe AK groups in the post hoc testing.
Discussion
In this study, we tested the psychometric properties of the AKQoL-NL. Our data suggest that the questionnaire is feasible. The results on reliability were inconsistent: the internal consistency was poor, but the repeatability was excellent and inter-item and inter-scale coefficients were lower than reported in the other versions of the AKQoL. The construct validity of the AKQoL-NL seems reasonable, as we observed reasonable correlation with a dermatological-specific HRQoL instrument (Skindex-17) and poor correlation with frailty in general (GFI). The discriminative validity was high for patients with severe AK compared to those with mild or moderate disease severity.
Feasibility
The AKQoL was developed in Denmark and to date only the translation into Spanish has been validated in two studies [9, 10] . Comparable to their results we also observed floor effects in items 6 and 8 [10] , but we observed floor effects in 3 other items as well. This indicates that most patients do not have difficulties due to their sun-damaged skin or feelings of guilt regarding their sundamaged skin. These items may, however, be valuable for distinguishing a smaller subgroup of patients with a more severe impact of AK on their HRQoL. Reliability As our results indicated poor internal consistency for the subscales, we would have liked to compare our results to the three other studies. However, the Danish as well as both of the Spanish studies only reported an overall Cronbach alpha, which ranged from 0.81 to 0.91, which was higher than our overall estimate (0.64). Combining multiple correlated constructs (emotion, function, control, global) into one scale (AKQoL overall) leads to a high Cronbach alpha by definition [19] . As the correlation between the domains in our study was lower compared to the Danish and the Spanish studies, as a logical result the Cronbach alpha of the overall AKQoL was also lower. The Cronbach alpha per subscale provides information about the correlation between the items of one construct. A problem of the Cronbach alpha is that it increases with the number of items. The AKQoL has only 1-3 items per subscale, which leads to a low Cronbach alpha per subscale. Analysis of the item-rest correlation within the scales showed good performance of the items (r > 0.20) with the exception of item 8 (r = 0.15). Unfortunately, both the Spanish as well as the Danish study did not report a Cronbach alpha per subscale, and therefore we are unable to determine if the correlation between the items of one domain is lower or comparable to other studies. In accordance with both Spanish validation studies the testretest correlation was high (> 0.9).
Validity
In order to establish convergent validity, the AKQoL was previously compared to both the Dermatology Life Quality Index (DLQI) and the Skindex-29. We compared the AKQoL with the Skindex-17 which led to correlation coefficients (0.226-0.376) comparable to the Skindex-29 (0.344) [9] . The correlation with the DLQI was much higher (> 0.75) [10] .
Our study adds information on divergent validity of the AKQoL. All previously performed studies did not compare the AKQoL with a generic HRQoL instrument. We have compared the AKQoL with the GFI, a general measure of frailty, which is an important determinant of generic HRQoL. As hypothesized, the GFI correlated very poorly with the AKQoL, indicating that the AKQoL specifically measures AK-related HRQoL impairment and does not measure poor well-being in general.
Our study also adds knowledge on the AKQoL performance in different severity groups. Both the Danish and the Spanish studies did not provide information on disease severity, possibly because it is difficult to count AKs [13] . Therefore, we assessed categories of AK count. We observed that the mean AKQoL scores differed between patients with mild or moderate AK and patients with severe AK. Patients with mild AK may have little to no impaired HRQoL due to their AK, which may explain the proportion of floor effects.
Strengths and Limitations
Strengths of our study include the high response rate and the inclusion of a large number of patients both in a general hospital as well as in a tertiary referral center. This led to a diverse group of patients in whom it was possible to assess the performance of the AKQoL by disease severity. Another strength of our study is that we included the GFI in order to assess divergent validity.
A limitation of this study is that the translation is based on the English version of the AKQoL, and not the original Danish version. Another limitation is that no information was gathered on the patients refusing to participate in this study.
Future Directions
As we have shown that the mean AKQoL score is different for severe AK patients, future research could assess the responsiveness of the AKQoL (i.e., if the AKQoL changes with treatment response). This is needed to determine if the AKQoL can be used in clinical trials for therapy.
Since the debate on whether to treat or not to treat AK is still ongoing [20] , the AKQoL may provide additional information for the individual patient to decide whether or not to treat. On a group level, on the other hand, it may help to identify patient groups eligible for treatment beforehand (e.g., elderly men with multiple AKs on the scalp).
Future studies should help to determine if the low internal consistency of the subscales is due to cultural differences or due to the design of the questionnaire. Therefore, the Cronbach alpha per subscale should be determined in future studies and, ideally, also that of the original Danish study.
Conclusion
Our study added important information on the validity of the AKQoL, showing that it has discriminative validity on disease severity and that it measures AK-specific HRQoL and not frailty in general. The internal consistency of the AKQoL-NL was poor, but the repeatability was excellent. The AKQoL-NL is a feasible and valid HRQoL instrument, but reliability is moderate and therefore the AKQoL-NL could be used as a tool to assess dis-
